3.4400 0.00 (0.00%)
After hours: 4:19PM EDT
|Bid||3.4400 x 3200|
|Ask||3.4500 x 4000|
|Day's Range||3.3800 - 3.6000|
|52 Week Range||3.0100 - 32.0500|
|Beta (3Y Monthly)||2.31|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 7, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||17.44|
Clovis Oncology, Inc. will announce its third quarter 2019 financial results on Thursday, November 7, 2019, before the open of the U.S. financial markets. Clovis’ senior management will host a conference call and live audio webcast at 8:30 a.m.
Clovis Oncology, Inc. today announced that the National Institute for Health and Care Excellence has recommended that women with relapsed ovarian cancer in England have access to rucaparib through the Cancer Drugs Fund .1 Rucaparib is available for use within the CDF as an option for the maintenance treatment of relapsed, platinum-sensitive high-grade epithelial ovarian, fallopian tube or primary peritoneal ...
Goldman Sachs lowers price target for Clovis' (CLVS) shares taking into account the risk of lower future revenues due to rising competition in the PARP inhibitor segment.
Belying the popular notion that oncology biotechs are lucrative investment options,Goldman Sachs is taking a bearish stance on Puma Biotechnology Inc (NASDAQ: PBYI ) and Clovis Oncology Inc (NASDAQ: CLVS ...
J&J (JNJ) announces that the FDA has granted Breakthrough Therapy status to its PARP inhibitor, niraparib, for the treatment for advanced prostate cancer.
BOULDER, Colo.-- -- 43.9% confirmed objective response rate in 57 RECIST * -evaluable patients with metastatic castration-resistant prostate cancer and a BRCA1/2 mutation 52.0% confirmed prostate-specific antigen response in 98 PSA-evaluable patients with mCRPC and a BRCA1/2 mutation The safety profile of Rubraca was consistent with prior reports from TRITON2 and for those patients with ovarian cancer ...
Clovis (CLVS) enters into licensing and collaboration agreement with 3B Pharmaceuticals and acquires rights to FAP targeted radiopharmaceutical therapy for developing new cancer treatments.
SVB Leerink analyst Andrew Berens said the company’s decision to license a targeted radiotherapy program from a private German biotechnology company was ill timed.
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Sept. 23.) Applied Therapeutics Inc (NASDAQ: APLT ) ...
Clovis to acquire rights to discovery program for three additional targets for radionuclide therapy
BOULDER, Colo.-- -- Updated data from the Phase 2 TRITON2 trial of Rubraca in patients with advanced metastatic castration-resistant prostate cancer Exploratory ARIEL3 analysis for Rubraca maintenance treatment regimen in ovarian cancer based on response to prior platinum-based chemotherapy Integrated safety analysis of Rubraca in ovarian cancer treatment and maintenance treatment settings Clovis Oncology, ...
President and CEO of Clovis Oncology Inc (30-Year Financial, Insider Trades) Patrick J Mahaffy (insider trades) bought 50,000 shares of CLVS on 08/16/2019 at an average price of $5.59 a share. Continue reading...
Last week, AstraZeneca plc (NYSE: AZN) reported positive results for its prostrate cancer treatment Lynparza for patients with certain genetic profiles. Ahmad wrote in a note on Tuesday that AstraZeneca’s incremental success changes the game for Clovis.